A Case of Tuberculous Meningitis With Concomitant Spinal Co-infection With Tuberculosis and <i>Aspergillosis</i>

Co-infection with <i>Mycobacterium tuberculosis</i> and <i>Aspergillus</i> in an immunocompetent host is rare but can occur. In this case, we present a patient with central nervous system tuberculosis (TB) and biopsy-proven spinal co-infections with TB and Aspergillosis. We highlight the complexities of treating a TB-Aspergillosis co-infection given drug-drug interactions between standard therapy for both conditions. Using susceptibilities for the <i>Aspergillus</i> and carefully monitoring drug levels of the antifungal agents, we were able to optimally treat the co-infection. This patient was ultimately discharged on isoniazid 1200 mg (15 mg/kg) daily, levofloxacin 750 mg daily, rifabutin 450 mg daily, and posaconazole 300 mg twice daily with a tentative plan to treat for at least 1 year with close outpatient follow-up. This case can serve as a guide for other providers who need to treat cases of TB and Aspergillosis co-infection by learning from our experience and paying attention to potential pitfalls.

Authors

Institutions

Publication Details

Journal
Journal of Investigative Medicine High Impact Case Reports
Published
2025-03-26
DOI
https://doi.org/10.1177/23247096251329684
Citations
2
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
2.79
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Case of Tuberculous Meningitis With Concomitant Spinal Co-infection With Tuberculosis and Aspergillosis

Folusakin Ayoade, Candice A. Sternberg, Ayoola Olayiwola, Christine Vu et al.
2 citations
Journal of Investigative Medicine High Impact Case Reports
Antifungal resistance and susceptibility
2.79
article

A Case of Tuberculous Meningitis With Concomitant Spinal Co-infection With Tuberculosis and Aspergillosis

Folusakin Ayoade, Candice A. Sternberg, Ayoola Olayiwola, Christine Vu, Tanya Quiroz, Nadine Montreuil, Andrés Martínez, Maria Morel Almonte
article en
2 citations

Abstract

Co-infection with <i>Mycobacterium tuberculosis</i> and <i>Aspergillus</i> in an immunocompetent host is rare but can occur. In this case, we present a patient with central nervous system tuberculosis (TB) and biopsy-proven spinal co-infections with TB and Aspergillosis. We highlight the complexities of treating a TB-Aspergillosis co-infection given drug-drug interactions between standard therapy for both conditions. Using susceptibilities for the <i>Aspergillus</i> and carefully monitoring drug levels of the antifungal agents, we were able to optimally treat the co-infection. This patient was ultimately discharged on isoniazid 1200 mg (15 mg/kg) daily, levofloxacin 750 mg daily, rifabutin 450 mg daily, and posaconazole 300 mg twice daily with a tentative plan to treat for at least 1 year with close outpatient follow-up. This case can serve as a guide for other providers who need to treat cases of TB and Aspergillosis co-infection by learning from our experience and paying attention to potential pitfalls.

Journal of Investigative Medicine High Impact Case ReportsVol. 13
University of Miami (US), Jackson Health System (US)
Good health and well-being
Openalex Percentile: Top 12%
Antifungal resistance and susceptibility
2.79
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.